



Contents lists available at BioMedSciDirect Publications

International Journal of Biological & Medical Research

Journal homepage: www.biomedscidirect.com

Case report

Clinical translation of the benefits of cell transplantation in a case of cerebral palsy

Alok Sharma, Pooja Kulkarni, Ritu Varghese*, Hemangi Sane, Sanket Inamdar, Jasbinder Kaur, Samson Nivins, Nandini Gokulchandran, Prerna Badhe

NeuroGen Brain & Spine Institute, Plot 19, Sector 40, Off Palm Beach Road, Seawoods (W), Navi Mumbai, Maharashtra, 400706. India

ARTICLE INFO

Keywords:

Autologous
bone marrow mononuclear cells
cell transplantation
cerebral palsy
positron emission tomography
computed tomography
stem cells.

ABSTRACT

Aims: Cerebral palsy (CP) is an umbrella term including a group of permanent disorders of development of movement and of posture causing activity limitation. Oxidative stress and glutamate mediated excitotoxicity are important mechanisms of injury to both the white matter and neurons in the developing brain resulting in motor deficits. No treatment measures are available that can repair the existing damage. Use of bone marrow stem cells for the treatment of CP has shown promise owing to their capacity for self-renewal, differentiation with a potential of neuroregeneration and secretory paracrine effects. **Methods:** To study the efficacy of cell transplantation in CP, we administered autologous bone marrow mononuclear cells intrathecally to a 2.2-year-old female patient. She was followed up at 9 months and a repeat transplantation was administered. A second follow up was done 5 months after second transplantation. Gross Motor Function Classification System-Expanded & Revised (GMFCS-E&R), Gross Motor Function Measure-88 (GMFM-88) and Functional Independence Measure for children (WeeFIM) were used as outcome measures to assess therapeutic efficacy. **Results:** 9 months after first transplantation, symptomatic improvements such as reduced spasticity, ability to crawl with reciprocal pattern, independent walking with walker, independent transfer from bed to floor, improved biting and chewing and cognition were observed. On GMFCS-E&R she improved from level III to level II, GMFM-88 improved from 36.36% to 38.62% and WeeFIM improved from 34 to 38. These improvements were well supported by positron emission tomography-computed tomography which showed improved metabolism in bilateral cerebellum and medial temporal cortex. All these improvements were maintained even at 5 months' follow up post second transplantation. No adverse events were reported after the procedures or at follow ups. **Conclusion:** Intrathecal administration of autologous bone marrow mononuclear cells are safe and an effective therapeutic strategy in the management of CP.

© Copyright 2010 BioMedSciDirect Publications IJBMR - ISSN: 0976:6685. All rights reserved.

Introduction

Cerebral palsy (CP) is an umbrella term including a group of permanent disorders of the development of movement and of posture causing activity limitation. It is caused due to non-progressive disturbances occurring in the developing fetal/infant brain [1]. Premature birth and intrapartum asphyxia are the most common causes of CP [2,3]. Oxidative stress that follows hypoxia, ischemia, or infection and glutamate mediated excitotoxicity are said to be important mechanisms of injury to both the white matter and neurons in the developing brain resulting in motor deficits [2]. The motor component of CP is mostly accompanied by disturbances in sensation, perception, cognition, communication, behavior, epilepsy and secondary musculoskeletal problems depending on the region and extent of damage [1]. Although the overall prevalence of CP is approximately 2 per 1000 live births, it is one of the most common causes of serious physical disability occurring in childhood [4].

Medical management of individuals with CP involves physicians offering primary care along with neurological, orthopedic and rehabilitation inputs. Conventional therapies include intramuscular injections of botulinum toxin A, high-protein diets, speech therapy, physical therapy, occupational therapy and orthopedic surgery [5,6]. However, none of these treatment measures can repair the existing damage. Recently, cell transplantation has gained importance as a treatment option for CP owing to its potential of neuroregeneration and neuroprotection demonstrated in the animal brain [7].

To study the efficacy of cell transplantation in CP, we administered cell transplantation to a 2 years and 2 months old female child with CP. Autologous bone marrow mononuclear cells were used for transplantation as their procurement requires a minimally invasive procedure, their safety has been established [8,9] and their use is not ethically restricted [10].

* Corresponding Author :
publications@neurogen.in

CASE PRESENTATION

Herein, we present a case of a 2.2-year-old female child diagnosed with CP. In the prenatal history, the mother suffered from chicken pox and was on medications for the same in the 8th week of gestation. The child was born at full term through caesarean section and cried immediately after birth. Her birth weight was normal. There was a history of meconium aspiration and breathing difficulty at birth for which she was in the neonatal intensive care for 9 days. The meconium was removed by suction and she was administered oxygen. A two-dimensional echocardiogram was done which revealed patent ductus arteriosus. A repeat two-dimensional echocardiogram echo to be changed to two-dimensional echocardiogram after 2 months revealed ductal closure.

At 9 months of age, parents noticed developmental delay and on consultation with pediatrician she was diagnosed as a case of CP. Magnetic resonance imaging brain was done which revealed bilateral subcortical and deep white matter abnormalities. The acquisition of the milestones is shown in Table 1 [11].

Before administration of bone marrow mononuclear cells, she was examined thoroughly by a team of experts. On examination, Babinski sign was positive with brisk deep tendon reflexes in the lower limbs, while deep tendon reflexes in the upper limbs were normal. There was an increased muscle tone in the plantar flexors, and knee flexors bilaterally. She presented with inability to sit from supine position. Standing balance was poor as she could not stand without support. She could not walk independently and was dependent for ambulation, transfers and bladder bowel hygiene. Her speech was limited to 2-3 words. Biting and chewing were affected and was fed semisolid food only. Cognition was affected as her understanding and concentration were poor. She failed to respond to her name or make eye contact. On the Gross Motor Function Classification System-Expanded & Revised (GMCS-E&R), she was at level III. On Gross Motor Function Measure-88 (GMFM-88) she scored 36.36%. On Functional Independence Measure for Children (WeeFIM), she scored 34.

Magnetic resonance imaging brain revealed diffuse paucity of the bilateral cerebral white matter and mild dilatation of the lateral ventricles. Magnetic resonance imaging-diffusion tensor imaging with fiber tracking was performed. It revealed mild diffuse attenuation of the bilateral cerebral fiber tracts. Brain positron emission tomography-computed tomography (PET-CT) scan revealed severely reduced 18F-fluorodeoxyglucose (FDG) uptake in bilateral cerebellar hemispheres. Mildly reduced FDG uptake was seen in bilateral thalami, hippocampi and amygdala. Rest of the brain parenchyma revealed preserved FDG uptake.

Materials and Methods

Patient selection was based on World Medical Association Helsinki Declaration [12]. Ethical approval was obtained from the Institutional Committee for Stem Cell Research and Therapy. A duly signed informed consent for the procedure was obtained from the patient's parents.

A detailed neurological examination was performed. Granulocyte colony-stimulating factor (G-CSF, 300 µg) injections were administered subcutaneously, 72 hours and 24 hours before the intervention to enhance the mobilization of bone marrow mononuclear cells [13].

On the day of cell transplantation, 70 ml of bone marrow was aspirated from the right anterior superior iliac spine and collected in heparinized tubes. The mononuclear cells were separated by the density gradient method. The purified mononuclear cells were checked for viability using trypan blue and confirmed using automated TALI machine. The viability of cells was found to be 98%. CD 34+ analysis of these cells was performed using fluorescence activated cell sorting. The total number of cells administered was 9.6×10^7 and their CD 34+ count was 0.58%. The mononuclear cells were diluted in the patient's own cerebrospinal fluid owing to its properties of harboring cell growth [14] and were injected intrathecally in the L4-L5 interspace. 200 mg methyl prednisolone in 500 ml Ringer Lactate solution was administered intravenously at the time of transplantation. Following transplantation, the patient underwent a multidisciplinary personalized neurorehabilitation program which included physiotherapy, occupational therapy, special education, speech therapy, psychological therapy, and nutritional advice. A personalized home program was given at discharge and was advised to continue rehabilitation regime at home. She was followed up at 9 months. To enhance the functional improvements seen after the first transplantation, the patient was administered a second transplantation of autologous bone marrow mononuclear cells with the same protocol as described above. The total number of cells administered was 4.20×10^8 and their CD 34+ count was 1.20%. The purified mononuclear cells were found to have a viability of 97%.

RESULTS

There were no side effects reported immediately after the intervention or at the subsequent follow ups.

9 months post first transplantation, the child could crawl with a reciprocal pattern and walk independently with the help of walker, which she was unable to do earlier. There was decrease in spasticity. She could independently transfer from the bed to the floor. She could perform reach out in all positions. Biting and chewing had also improved and she could eat food items such as a biscuit. On GMFCS-E&R, she moved from level III to level II. GMFM score improved from 36.36% to 38.62%. On WeeFIM she improved from 34 to 38.

Cognitive improvements were observed. Her understanding had improved. She could follow simple commands. She made more eye contact with her parents, and started responding to her name. She could now indicate that she was hungry by crying, making it easier for her parents to understand. Awareness of the surroundings had improved. She started to play more and mingle with her sister. Before intervention she would pass urine and stools in the diaper. But now she would get down from the bed to the floor, indicating to the mother her urge to pass urine/stools. Alertness also improved.

5 months post second transplantation, all the above-mentioned improvements were maintained. In addition, she was now toilet trained and passed urine/stools in potty chair only.

Comparative PET CT performed 9 months post intervention showed improved metabolism in bilateral cerebellum, bilateral thalami and medial temporal cortex including hippocampus and amygdala.

Figure 1. Comparative PET CT before and after cell transplantation




Figure 1. The F-18 FDG-PET of the brain were obtained and co-registered with CT. The cross-sections of the fused images in coronal, sagittal and axial views. Top row (A) represents PET CT scan before the intervention of cell transplantation. Bottom row (B) represents a 9-month follow-up PET CT scan after cell transplantation. Post transplantation shows significant improvement in uptake corresponding to medial temporal cortex (MT), cerebellum (C) and thalamus (T).

Table1. Gross Motor Developmental History

Domain of development	Milestones	Patient's age at milestone attainment	Normal child's expected age at milestone attainment
Gross motor	Head control	10-11 months	1-4 months
	Rolling	17-18 months	4 months
	Sitting with support	13 months	5-6 months
	Sitting without support	20 months	6-8 months
	Crawling	Not achieved	8-9 months
	Standing with support	24 months	6-11 months
	Standing independently	Not achieved	12 months
	cruising	23 months	10 months

Table 2. Brain areas showing improvement on PET CT with corresponding functional improvements

Brain areas showing improvement on PET CT	Functional improvements
Cerebellum	Improvement in motor functions, balance and posture, cognitive functions [31].
Medial temporal cortex	Learning and memory [32]
thalamus	Alertness

DISCUSSION

CP can be divided into subtypes based on tone abnormalities, as spastic, ataxic, or dyskinetic and based on the distribution of limb weakness, as bilateral or unilateral CP [15]. Most cases of CP do not occur due to a single causative factor, but through an interaction of prenatal, perinatal acute or subacute, and postnatal factors that affect brain maturation. These factors contribute to the hypoxic-ischemic brain injury. Hypoxic-ischemia results in a cascade of events including production of proinflammatory cytokines, oxidative stress, deprivation of growth factors, extracellular matrix modification and excessive release of glutamate, causing cell death, predominantly in the white matter in preterm infants and the gray matter in full-term infants [16]. These disturbances result in activation of neutrophils, macrophages and microglia leading to direct or indirect neuronal and preoligodendrocyte cell death or dysfunction [17]. Studies have suggested that the immature white matter can also be damaged by excessive release of glutamates [18]. Gray matter abnormalities in cortical and deep nuclear structures and cerebellar abnormalities may occur and contribute to development of cognitive and psychomotor delays [17]. The treatment of CP is restricted and aimed at increasing functional independence through pharmacotherapy, rehabilitation and use of assistive devices and functional aids [19]. But, these have failed to provide satisfactory benefits. Extensive research has presented stem cell therapy as a treatment option due to their ability to target the underlying pathological mechanisms in CP [20].

In our case, we administered autologous bone marrow mononuclear cells intrathecally. Studies have provided evidence that these cells survive and selectively migrate to injured areas, providing therapeutic benefits in diseases of the central nervous system [21]. Due to avoidance of the risk of immune rejection, autologous cells possess an advantage over allogenic cells [20,22]. Intrathecal route of administration was used to ensure application into the central nervous system and because cerebrospinal fluid possesses properties which support cell growth [14]. Though, the exact mechanism of bone marrow mononuclear cells remains unclear, several mechanisms of action are believed to be involved. The secretion of neurotrophic and growth factors may be the most important mechanism by which bone marrow mononuclear cells

produce therapeutic benefits [23,24]. These cells can migrate to the sites of damage and secrete neurotrophins and growth factors, which influence the microenvironment in the damaged area. Neurotrophins and growth factors such as connective tissue growth factor, transforming growth factor beta 1 (TGF β 1), fibroblast growth factors (FGF), vascular endothelial growth factor (VEGF) and nerve growth factor beta (NGF β) are known to promote neuroprotective and neurorestorative mechanisms in the central nervous system. Neurotrophic factors promote neuronal sprouting, synaptogenesis and increase in neurotransmitter release with increase in neurotransmission [24]. FGF may reduce the size of ischemia and promote migration and proliferation of stem cells [24]. TGF β 1 and VEGF, exhibit neuroprotective effect against ischemia induced apoptosis. Bone marrow mononuclear cells secrete a variety of cytokines which promote hematopoietic cells to adhere to the endothelium promoting angiogenesis [25]. Exosomes which are membrane enclosed vesicles responsible for cell-cell communication are generated by bone marrow mononuclear cells. Exosomes are believed to enhance neurite remodeling, and angiogenesis and may further contribute to functional recovery [26,27]. Administered bone marrow mononuclear cells may also differentiate into oligodendrocytes and replace the damaged/ lost ones and promote functional improvement in the affected motor tracts through promotion of remyelination [23,28]. Thus, cell transplantation with bone marrow mononuclear cells possesses the potential to address the core pathogenesis of CP.

Our case study provides evidence of the therapeutic benefits of bone marrow mononuclear cell transplantation. There were no adverse events noted immediately after the procedure or at the subsequent follow-ups. The patient showed improved motor functions and cognitive functions which eventually led to functional improvements. The GMFM measures gross motor function in children with CP. The GMFCS-E&R reflects the degree of function and independence in CP afflicted children. The GMFM and GMFCS-E&R are reliable and frequently used tools to evaluate the outcome of an intervention in children with CP [29]. With the child improving functionally, there was improvement recorded on both scales consecutively.

Brain PET CT using FDG was used to monitor disease activity and to determine response to therapy at cellular level. It measures the cerebral metabolic activity, providing the functional status and is also able to measure any alteration in metabolic activity [30]. Increase in FDG uptake compared to pre-intervention was seen in bilateral cerebellum, medial temporal cortex including the hippocampus and amygdala and in bilateral thalami after intervention. Thus, the improvement in motor functions, balance, posture and cognition seen in our patient were well correlated with the changes seen on the PET CT (Refer to Figure 1, Table 2).

PET CT findings supported by functional and motor improvements confirm the therapeutic benefits of bone marrow mononuclear cell transplantation in our case study. However, this is a single case study and hence, may require more evidence to establish its change therapeutic efficacy to therapeutic efficacy.

CONCLUSION

Intrathecal administration of autologous bone marrow mononuclear cells is safe and can be a therapeutic strategy in combination with available conventional treatments for management of CP. To objectively monitor the treatment outcome, PET CT brain can be used as it evaluates the outcome at cellular level with respect to metabolic changes occurring in the brain post intervention. Autologous bone marrow mononuclear cell transplantation in combination with neurorehabilitation helps the CP patients regain their lost functions and make them functionally independent and as a result improve their quality of life. Cell transplantation can promote acquisition of developmental milestones in CP.

REFERENCES

1. Baxter P, Morris C, Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Colver A, Damiano D, Graham HK, Brien GO. The definition and classification of cerebral palsy. *Dev Med Child Neurol.* 2007; 49(s109):1-44.
2. Johnston M, Hoon A. Cerebral Palsy. *NeuroMolecular Medicine.* 2006;8(4):435-450.
3. Hagberg G, Hagberg E, Beckung P, B. Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth year period 1991-94. *Acta Paediatrica.* 2001; 90(3):271-277.
4. Oskoui M, Coutinho F, Dykeman J, Jetté N, Pringsheim T. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. *Developmental Medicine & Child Neurology.* 2013; 55(6):509-519.
5. Aisen ML, Kerkovich D, Mast J, Mulroy S, Wren TA, Kay RM, Rethlefsen SA. Cerebral palsy: clinical care and neurological rehabilitation. *Lancet Neurol.* 2011; 10(9):844-852.
6. Holt RL, Mikati MA. Care for child development: basic science rationale and effects of interventions. *Pediatric neurology.* 2011; 44(4):239-253.
7. Titomanlio L, Kavelaars A, Dalous J, Mani S, El Ghouzzi V, Heijnen C, Baud O, Gressens P. Stem cell therapy for neonatal brain injury: perspectives and challenges. *Annals of neurology.* 2011; 70(5):698-712.
8. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassir I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavov S. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Archives of neurology.* 2010; 67(10):1187-1194.
9. Gubert F, Satiago MF. Prospects for bone marrow cell therapy in amyotrophic lateral sclerosis: how far are we from a clinical treatment? *Neural regeneration research.* 2016; 11(8):1216.
10. Ganz J, Lev N, Melamed E, Offen D. Cell replacement therapy for Parkinson's disease: how close are we to the clinic? *Expert Review of Neurotherapeutics.* 2011; 11(9):1325-1339.
11. Nair M, Nair G, George B, Suma N, Neethu C, Leena M, Russell P. Development and Validation of Trivandrum Development Screening Chart for Children Aged 0-6 years [TDSC (0-6)]. *The Indian Journal of Pediatrics.* 2013; 80(S2):248-255.
12. Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. *British journal of clinical pharmacology.* 2004; 57(6):695-713.
13. Haas R, Murea S. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. *Cytokines and molecular therapy.* 1995; 1(4):249-270.
14. Miyan JA, Zendah M, Mashayekhi F, Owen-Lynch PJ. Cerebrospinal fluid supports viability and proliferation of cortical cells in vitro, mirroring in vivo development. *Cerebrospinal fluid research.* 2006; 3(1):2.

15. McAdams RM, Juul SE. Cerebral palsy: prevalence, predictability, and parental counseling. *NeoReviews*. 2011;12(10):e564-574.
16. Marret S, Vanhulle C, Laquerriere A. Pathophysiology of cerebral palsy. *Handbook of Clinical Neurology*. 2013; 111:169-176.
17. McAdams RM, Juul SE. The role of cytokines and inflammatory cells in perinatal brain injury. *Neurology research international*. 2012;2012.
18. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. *Journal of Neuroscience*. 2000; 20(24):9235-41.
19. Chung CY, Chen CL, Wong AM. Pharmacotherapy of spasticity in children with cerebral palsy. *Journal of the Formosan Medical Association*. 2011; 110(4):215-222.
20. Dailey T, Mosley Y, Pabon M, Acosta S, Tajiri N, van Loveren H, Kaneko Y, Borlongan CV. Advancing critical care medicine with stem cell therapy and hypothermia for cerebral palsy. *NeuroReport*. 2013; 24(18):1067.
21. Grove JE, Bruscia E, Krause DS. Plasticity of bone marrow-derived stem cells. *Stem cells*. 2004; 22(4):487-500.
22. Prasongchean W, Ferretti P. Autologous stem cells for personalised medicine. *New biotechnology*. 2012; 29(6):641-650.
23. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. *Experimental neurology*. 2002; 174(1):11-20.
24. Qu R, Li Y, Gao Q, Shen L, Zhang J, Liu Z, Chen X, Chopp M. Neurotrophic and growth factor gene expression profiling of mouse bone marrow stromal cells induced by ischemic brain extracts. *Neuropathology*. 2007; 27(4):355-363.
25. Maeda Y, Ikeda U. The Role of Vascular Endothelial Growth Factor (VEGF) on Therapeutic Angiogenesis Using Bone Marrow Cells. In: *Cardiovascular Regeneration Therapies Using Tissue Engineering Approaches*. Mori H, Matsuda H (eds). Springer, Tokyo, 2005, pp 173-180.
26. Lopez-Verrilli MA, Caviades A, Cabrera A, Sandoval S, Wyneken U, Khoury M. Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. *Neuroscience*. 2016; 320:129-139.
27. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, Shang X, Zhang ZG, Chopp M. Exosome-Mediated Transfer of miR-133b from Multipotent Mesenchymal Stromal Cells to Neural Cells Contributes to Neurite Outgrowth. *Stem cells*. 2012; 30(7):1556-1564.
28. Sasaki M, Honmou O, Akiyama Y, Uede T, Hashi K, Kocsis J. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. *Glia*. 2001; 35(1):26-34.
29. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Developmental Medicine & Child Neurology*. 1997; 39(4):214-223.
30. Jamieson D, Alavi A, Jolles P, Chawluk J, Reivich M. Positron emission tomography in the investigation of central nervous system disorders. *Radiologic Clinics of North America*. 1988; 26(5):1075-1088.
31. Schmahmann J. Cognition, emotion and the cerebellum. *Brain*. 2005;129(2):290-292.
32. Squire LR, Stark CE, Clark RE. The medial temporal lobe. *Annu. Rev. Neurosci*. 2004; 27:279-306.